The molecule does not replace the product
Think of a bottle without a label. Knowing it contains CBD does not yet tell us its full composition, concentration, purpose, who is responsible for it or what documentation accompanies it. Those pieces of information are needed to assess it. A chemical name may begin an enquiry, but it cannot, on its own, settle a legal conclusion.
The same applies to a shop's country. A website being in French or Czech, or offering delivery to Spain, does not establish that its product complies with requirements for the Spanish market. Commercial availability is something we can observe; conformity requires examining requirements. Confusing the two turns a checkout screen into a certificate it is not.
Food: assessment and authorisation are different steps
In its 2026 information, AESAN explains that marketing CBD as food depends on its authorisation as a novel food. The European Commission describes a procedure in which scientific assessment and the authorisation act serve different functions. A favourable opinion on a particular application does not automatically authorise every formulation or an entire catalogue.
When reading a news story, look for the exact verb. Applying, assessing, concluding and authorising are not interchangeable. Then identify the ingredient, specifications and conditions covered by the document. This avoids both announcing a permission that does not exist and denying real scientific progress. A product's situation should be checked against current regulatory documentation, not summarised from the latest headline.
Cosmetics: a purpose and a dossier
Cosmetics have their own framework. An ingredient's mere presence in CosIng does not amount to approval for use: the Commission expressly warns of this in the database information. A commercial formulation requires consideration of the whole product and its obligations, as well as the ingredient's identity.
A hypothetical example helps make this clear. Two creams may mention CBD while differing in composition, presentation and documentation. It would be wrong to validate the second simply because the first exists. Similar wording is not enough either. Useful reading connects each commercial claim to the specific product it purports to describe.
The healthcare route follows a different logic
Royal Decree 903/2025 regulates conditions for preparing and dispensing standardised magistral formulations of standardised cannabis preparations. This healthcare regulation should not be interpreted as a general authorisation for items in a shop. Two products sharing a substance or a plant image does not make them equivalent.
For readers, the practical distinction is conceptual: a consumer product does not inherit a medicine's indications, controls or instructions. Nor does news about healthcare access automatically answer a question about food or cosmetics. Keeping those routes separate makes it easier to understand what has actually changed when a new rule appears.
A set of questions that helps
Before accepting a claim of legality, identify the product, its composition, the use for which it is offered, the responsible party and the regulatory source cited. Then check whether the document addresses that case or a different one. A laboratory analysis provides information about the sample; it does not settle all those questions on its own.
This guide reflects a documentary review as of 31 October 2026 and provides general orientation, not validation of a particular product. The best answer is not always the shortest. In a subject where categories matter so much, an explanation of what needs checking is more useful than a universal permitted or prohibited label attached to three letters.
A page's date also deserves attention. A text published years ago may accurately describe its own moment while needing review for a current enquiry. Keep the original reference and check which later documents amend, develop or clarify its content before applying it to the present.
Take this with you
Legal status is assessed by product, purpose and requirements; CBD is not one single commercial category.
Sources you can open
The source may be in its original language. English publication does not change the jurisdiction or date discussed.
Follow the thread
Open the cannabinoid encyclopedia
Check the identity, research, uncertainties and documented forms of each compound.